Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (281-290 of 333) with videos related to

Pageof 34
Sort By:
Journal of Viral Hepatitis|April 12, 2019
Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis BAdrian M Di Bisceglie, Wendy C King, Mauricio Lisker-Melman, et al.
Hepatology (Baltimore, Md.)|November 7, 2021
Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohortNorah A Terrault, Abdus S Wahed, Jordan J Feld, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 16, 2025
Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trialChristopher Kandel, Mia J Biondi, Mark Gillrie, et al.
Hepatology Communications|December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trialSanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
Gut|November 6, 2025
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)Edo J Dongelmans, Lesley A Patmore, Seng Gee Lim, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
Nature Communications|January 31, 2019
Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusionMarcos Galasso, Jordan J Feld, Yui Watanabe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 17, 2025
Association of metabolic comorbidities with fibrosis severity and fibrosis regression in patients with chronic hepatitis BLisa M van Velsen, Lesley A Patmore, Jordan J Feld, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 2, 2023
Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis BLesley A Patmore, Warshan K Katwaroe, Daniel van der Spek, et al.
Journal of Viral Hepatitis|January 19, 2024
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study)Mina S Farag, Margo J H van Campenhout, M J Sonneveld, et al.
Pageof 34

Showing results (281-290 of 333) with videos related to

Sort By:
Pageof 34
Journal of Viral Hepatitis|April 12, 2019
Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis BAdrian M Di Bisceglie, Wendy C King, Mauricio Lisker-Melman, et al.
Hepatology (Baltimore, Md.)|November 7, 2021
Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohortNorah A Terrault, Abdus S Wahed, Jordan J Feld, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 16, 2025
Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trialChristopher Kandel, Mia J Biondi, Mark Gillrie, et al.
Hepatology Communications|December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trialSanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
Gut|November 6, 2025
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)Edo J Dongelmans, Lesley A Patmore, Seng Gee Lim, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
Nature Communications|January 31, 2019
Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusionMarcos Galasso, Jordan J Feld, Yui Watanabe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 17, 2025
Association of metabolic comorbidities with fibrosis severity and fibrosis regression in patients with chronic hepatitis BLisa M van Velsen, Lesley A Patmore, Jordan J Feld, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 2, 2023
Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis BLesley A Patmore, Warshan K Katwaroe, Daniel van der Spek, et al.
Journal of Viral Hepatitis|January 19, 2024
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study)Mina S Farag, Margo J H van Campenhout, M J Sonneveld, et al.
Pageof 34